Article
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.
Oncogene - 20 Apr 2017
Harrod A, Fulton J, Nguyen V T M, Periyasamy M, Ramos-Garcia L, Lai C-F, Metodieva G, de Giorgio A, Williams R L, Santos D B, Gomez P J, Lin M-L, Metodiev M V, Stebbing J, Castellano L, Magnani L, Coombes R C, Buluwela L, Ali S
Abstract excerpt
Drugs that inhibit estrogen receptor-α (ER) activity have been highly successful in treating and reducing breast cancer progression in ER-positive disease. However, resistance to these therapies presents a major clinical problem. Recent genetic studies have shown that mutations in the ER gene are found in >20% of tumours that progress on endocrine therapies. Remarkably, the great majority of these mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.